Jobiba Chinkhumba
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jobiba Chinkhumba has a total of 147 co-authors. Here are the top co-authors by number of shared publications:
- Chantal M. Morel
Institute for Public Health & Hygiene, University Hospital Bonn, 53127 Bonn, Germany
4 shared publications - Chisomo Msefula
Pathology Department, Kamuzu University of Health Sciences, Blantyre 312200, Malawi
4 shared publications - Don Pascal Mathanga
Malaria Alert Centre, College of Medicine, University of Malawi, Blantyre, Malawi
4 shared publications - Edward Masoambeta
Health Systems and Policy Department, Kamuzu University of Health Sciences, Blantyre 312200, Malawi
4 shared publications - Luigia Scudeller
Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
4 shared publications - Adamson Sinjani Muula
Kamuzu University of Health Sciences
3 shared publications
Latest Publications
- Open Access
- 30 September 2026
- Published by MDPI AG in Tropical Medicine and Infectious Disease
- Vol. 11 (10) , 276
Estimating Economic Costs Associated with Treating Antimicrobial-Resistant Infections in Humans in Malawi
Background: Antimicrobial resistance (AMR) poses a significant threat to global health and economic development. In Malawi, the economic costs associated with the treatment of AMR infections remain largely unknown which may hinder resource allocation and policy prioritization. Method: The study used a cross-sectional design and was conducted between September 2023 and January 2025 at three different hospital settings. Data were collected from inpatients with laboratory-confirmed urinary tract infection (UTI) or blood stream infection (BSI). Additional follow-up data were collected from patients for four weeks post discharge. We analyzed patient level data first using descriptive statistics and employed an instrumental variable 2-stage least squares regression to estimate drivers of AMR treatments costs. Results: A total of 610 patients participated in the study. Of these, 45% had AMR-associated resistant infections. Overall, E. coli (43%) followed by P. aeruginosa (22%), K. pneumoniae (14%), and S. aureus (10%) were the most common pathogens. UTI was marginally more common (51%) compared to BSI (49%). BSI had a higher average cost than UTI for patients with both susceptible and resistant infections. On average, a patient spent MK283,815.10 (US$163.71) ranging from zero to MK13,500,000 (US$7786.90). Patients with resistant infections incurred, on average, MK161,785 (US$93.32) more than patients with susceptible infections, largely driven by prolonged hospitalization among other factors. Overall, the direct medical observed costs averaged MK37,165.29 (US$21.44) while direct non-medical observed costs averaged MK61,908.71 (US$35.71). Productivity losses for the patient and guardian(s) were a major observed cost averaging MK160,322.80 (US$92.49). The regression results further showed that having a bank account as a proxy of wealth, non-farm business, longer travel duration, BSI, and K. pneumoniae as the causative pathogens were significantly associated with increased cost burden among the patients. Conclusions: AMR-associated infections impose substantial economic burden on patients and households. Further strengthening of AMR surveillance and stewardship are needed as critical elements of Malawi’s National Action Plan. However, measures should also be taken to mitigate the economic consequences related to AMR, especially for patients who bear the brunt of these costs for lack of financial protection in Malawi’s health system.
- 30 September 2026
- Published by MDPI AG in Tropical Medicine and Infectious Disease
- Vol. 11 (10) , 276
Open AccessEstimating Economic Costs Associated with Treating Antimicrobial-Resistant Infections in Humans in Malawi
Background: Antimicrobial resistance (AMR) poses a significant threat to global health and economic development. In Malawi, the economic costs associated with the treatment of AMR infections remain largely unknown which may hinder resource allocation and policy prioritization. Method: The study used a cross-sectional design and was conducted between September 2023 and January 2025 at three different hospital settings. Data were collected from inpatients with laboratory-confirmed urinary tract infection (UTI) or blood stream infection (BSI). Additional follow-up data were collected from patients for four weeks post discharge. We analyzed patient level data first using descriptive statistics and employed an instrumental variable 2-stage least squares regression to estimate drivers of AMR treatments costs. Results: A total of 610 patients participated in the study. Of these, 45% had AMR-associated resistant infections. Overall, E. coli (43%) followed by P. aeruginosa (22%), K. pneumoniae (14%), and S. aureus (10%) were the most common pathogens. UTI was marginally more common (51%) compared to BSI (49%). BSI had a higher average cost than UTI for patients with both susceptible and resistant infections. On average, a patient spent MK283,815.10 (US$163.71) ranging from zero to MK13,500,000 (US$7786.90). Patients with resistant infections incurred, on average, MK161,785 (US$93.32) more than patients with susceptible infections, largely driven by prolonged hospitalization among other factors. Overall, the direct medical observed costs averaged MK37,165.29 (US$21.44) while direct non-medical observed costs averaged MK61,908.71 (US$35.71). Productivity losses for the patient and guardian(s) were a major observed cost averaging MK160,322.80 (US$92.49). The regression results further showed that having a bank account as a proxy of wealth, non-farm business, longer travel duration, BSI, and K. pneumoniae as the causative pathogens were significantly associated with increased cost burden among the patients. Conclusions: AMR-associated infections impose substantial economic burden on patients and households. Further strengthening of AMR surveillance and stewardship are needed as critical elements of Malawi’s National Action Plan. However, measures should also be taken to mitigate the economic consequences related to AMR, especially for patients who bear the brunt of these costs for lack of financial protection in Malawi’s health system.
- Open Access
- 12 August 2026
- Published by BMJ in BMJ Paediatrics Open
- Vol. 10 (1) , e004957
Cost-effectiveness of the IMPALA monitoring system for hospitalised children in low-resource settings: a pragmatic before-and-after study
Background: Staff shortages, limited training and inadequate hospital equipment often delay responses to patient deterioration in low-resource settings. The IMPALA continuous monitoring system was developed to support proactive care for critically ill children in such settings. This study evaluated IMPALA cost-effectiveness compared with current practice manual intermittent monitoring from provider and societal perspectives. Methods: We conducted an economic evaluation based on a before-and-after cohort of children (0–180 months) admitted to Zomba Central Hospital (ZCH) and St. Luke’s Hospital (SLH), Malawi (2022–2024), where IMPALA was implemented in high-dependency units (HDUs). Targeted maximum likelihood estimation assessed percentage point (pp) differences in mortality, critical illness events (CIEs), disability-adjusted life years (DALYs) and costs (medical, non-medical, indirect). Incremental cost-effectiveness ratios (ICERs) and cost-effectiveness probabilities were calculated for different willingness-to-pay thresholds. Results: At ZCH paediatric ward, 1840 pre-IMPALA and 6255 post-IMPALA children were included; 248 and 736 were admitted to the HDU. Ward mortality decreased (from 3.8% to 2.8%), with an adjusted 1.9 pp reduction (95% CI −3.8 to −0.6). At ZCH-HDU, mortality slightly increased (from 8.1% to 9.0%), but IMPALA was associated with an adjusted 9.8 pp reduction (95% CI −26.5 to 5.0), a 47.1 pp decrease in CIEs (95% CI −52.9 to −41.8), and 5.4 DALYs averted (95% CI −14.2 to 3.1). At SLH paediatric ward, 930 pre-IMPALA and 1126 post-IMPALA children were included. Mortality in SLH decreased (from 4.0% to 2.1%), with an adjusted 1.6 pp reduction (95% CI −3.2 to −0.2), a 25.5 pp decrease in CIEs (95% CI −30.1 to −20.9) and 1.0 DALYs averted (95% CI −1.9 to −0.1). Provider and societal costs decreased in both wards, but not in the HDU. IMPALA was dominant in wards and slightly more costly but more effective in the HDU (ICERs -$22.5–$0.4 per life saved). Cost-effectiveness probabilities ranged from 0.8 to 1.0 in wards and 0.3–1.0 in the HDU. Conclusion: IMPALA was highly cost-effective, reducing mortality by >40%, morbidity by >50%, increasing DALYs averted, shortening hospital stays and lowering costs, with spillover benefits from HDUs to wards.
- 12 August 2026
- Published by BMJ in BMJ Paediatrics Open
- Vol. 10 (1) , e004957
Open AccessCost-effectiveness of the IMPALA monitoring system for hospitalised children in low-resource settings: a pragmatic before-and-after study
Background: Staff shortages, limited training and inadequate hospital equipment often delay responses to patient deterioration in low-resource settings. The IMPALA continuous monitoring system was developed to support proactive care for critically ill children in such settings. This study evaluated IMPALA cost-effectiveness compared with current practice manual intermittent monitoring from provider and societal perspectives. Methods: We conducted an economic evaluation based on a before-and-after cohort of children (0–180 months) admitted to Zomba Central Hospital (ZCH) and St. Luke’s Hospital (SLH), Malawi (2022–2024), where IMPALA was implemented in high-dependency units (HDUs). Targeted maximum likelihood estimation assessed percentage point (pp) differences in mortality, critical illness events (CIEs), disability-adjusted life years (DALYs) and costs (medical, non-medical, indirect). Incremental cost-effectiveness ratios (ICERs) and cost-effectiveness probabilities were calculated for different willingness-to-pay thresholds. Results: At ZCH paediatric ward, 1840 pre-IMPALA and 6255 post-IMPALA children were included; 248 and 736 were admitted to the HDU. Ward mortality decreased (from 3.8% to 2.8%), with an adjusted 1.9 pp reduction (95% CI −3.8 to −0.6). At ZCH-HDU, mortality slightly increased (from 8.1% to 9.0%), but IMPALA was associated with an adjusted 9.8 pp reduction (95% CI −26.5 to 5.0), a 47.1 pp decrease in CIEs (95% CI −52.9 to −41.8), and 5.4 DALYs averted (95% CI −14.2 to 3.1). At SLH paediatric ward, 930 pre-IMPALA and 1126 post-IMPALA children were included. Mortality in SLH decreased (from 4.0% to 2.1%), with an adjusted 1.6 pp reduction (95% CI −3.2 to −0.2), a 25.5 pp decrease in CIEs (95% CI −30.1 to −20.9) and 1.0 DALYs averted (95% CI −1.9 to −0.1). Provider and societal costs decreased in both wards, but not in the HDU. IMPALA was dominant in wards and slightly more costly but more effective in the HDU (ICERs -$22.5–$0.4 per life saved). Cost-effectiveness probabilities ranged from 0.8 to 1.0 in wards and 0.3–1.0 in the HDU. Conclusion: IMPALA was highly cost-effective, reducing mortality by >40%, morbidity by >50%, increasing DALYs averted, shortening hospital stays and lowering costs, with spillover benefits from HDUs to wards.
- Open Access
- 6 August 2026
- Published by MDPI AG in Preprints.org
Estimating Economic Costs Associated with Treating Antimicrobial Resistant Infections in Humans in Malawi
Background: Antimicrobial resistance (AMR) poses a significant threat to global health and economic development. In Malawi, the economic costs associated with AMR remain largely unknown which may hinder resource allocation and policy prioritization. Method: The study used instrumental variable 2-stage least squares regression to analyze patient level cost data at tertiary and secondary level facilities primarily collected from 610 patients with urinary tract infection (UTI) or blood stream infection (BSI) using a questionnaire. Results: Findings indicate that E. coli (43%) followed by K. pneumoniae (14%), and S. aureus (10%) were common pathogens overall. UTI was common (51%) compared to BSI (49%) yet BSI had a higher average cost than UTI for both susceptible and resistant patient categories. In terms of costs, a patient spent MK283,815.10 (US$163.71) on average as a result of AMR infection. The total cost reached as high as MK13,500,000 (US$7,786.90). Patients with a resistant infection incurred, on average MK161,785 (US$93.32) more than patients whose infection was susceptible, with the additional costs being driven by prolonged hospitalization among other factors. The direct medical costs averaged MK37,165.29 (US$21.44) while direct non-medical costs averaged MK61,908.71 (US$35.71). Productivity losses for the patient and guardian(s) were a major cost averaging MK160,322.80 (US$92.49). The regression results further showed that having a bank account as a proxy of wealth, non-farm business, longer travel duration, BSI, and K. pneumoniae as causing pathogens were significantly associated with increased cost burden among the patients. Conclusions: AMR imposes substantial economic burden on Malawi's health system, with most costs falling on patients. Further strengthening of AMR surveillance and stewardship are needed as critical elements of Malawi’s National Action Plan. However, measures should also be taken to mitigate the economic consequences related to AMR, especially for patients who bear the brunt of these costs for lack of financial protection in Malawi’s health system.
- 6 August 2026
- Published by MDPI AG in Preprints.org
Open AccessEstimating Economic Costs Associated with Treating Antimicrobial Resistant Infections in Humans in Malawi
Background: Antimicrobial resistance (AMR) poses a significant threat to global health and economic development. In Malawi, the economic costs associated with AMR remain largely unknown which may hinder resource allocation and policy prioritization. Method: The study used instrumental variable 2-stage least squares regression to analyze patient level cost data at tertiary and secondary level facilities primarily collected from 610 patients with urinary tract infection (UTI) or blood stream infection (BSI) using a questionnaire. Results: Findings indicate that E. coli (43%) followed by K. pneumoniae (14%), and S. aureus (10%) were common pathogens overall. UTI was common (51%) compared to BSI (49%) yet BSI had a higher average cost than UTI for both susceptible and resistant patient categories. In terms of costs, a patient spent MK283,815.10 (US$163.71) on average as a result of AMR infection. The total cost reached as high as MK13,500,000 (US$7,786.90). Patients with a resistant infection incurred, on average MK161,785 (US$93.32) more than patients whose infection was susceptible, with the additional costs being driven by prolonged hospitalization among other factors. The direct medical costs averaged MK37,165.29 (US$21.44) while direct non-medical costs averaged MK61,908.71 (US$35.71). Productivity losses for the patient and guardian(s) were a major cost averaging MK160,322.80 (US$92.49). The regression results further showed that having a bank account as a proxy of wealth, non-farm business, longer travel duration, BSI, and K. pneumoniae as causing pathogens were significantly associated with increased cost burden among the patients. Conclusions: AMR imposes substantial economic burden on Malawi's health system, with most costs falling on patients. Further strengthening of AMR surveillance and stewardship are needed as critical elements of Malawi’s National Action Plan. However, measures should also be taken to mitigate the economic consequences related to AMR, especially for patients who bear the brunt of these costs for lack of financial protection in Malawi’s health system.
- Open Access
Modelling the Cost-Effectiveness of a Placental Malaria Vaccine in Sub-Saharan Africa
Introduction: Placental malaria increases the risk of adverse birth outcomes. Current preventive measures are undermined by poor coverage, growing resistance to chemo-preventive and therapeutic drugs, and vector eliminating insecticides. Candidate placental malaria (PM) vaccines (PAMVAC and PRIMVAC) have shown safety and immunogenicity in Phase I trials, but empirical evidence on their potential population-level value is lacking. This study modelled the expected cost-effectiveness of a PM vaccine administered before pregnancy. Methods: A decision-analytic model compared two strategies from the provider’s perspective: vaccinating women of childbearing age versus no vaccination. The model incorporated gravidity-specific risks of PM, neonatal mortality and the malaria attributable fractions from the literature. Since the efficacy of a PM vaccine for malaria prevention is unknown, we assumed a 40% efficacy and varied this estimate widely in sensitivity analyses. Primary outcomes were incremental cost-effectiveness ratios (ICERs) per perinatal disability adjusted life years (DALYs) averted. Baseline, best-case, and worst-case scenarios were analysed. One-way and probabilistic sensitivity analyses were used to assess parameter uncertainty. Cost-effectiveness was defined as an ICER below half of sub- Saharan Africa’s 2025 GDP per capita ($1556). Results: The vaccine was most cost-effective among primigravidae. Under baseline assumptions (40% efficacy; 30% uptake; $5 dose price), the ICER was $321 per perinatal DALY averted for primigravidae versus $4444 for multigravidae. Best-case assumptions further improved cost-effectiveness ($225 vs. $3148). Sensitivity analyses showed robust cost-effectiveness for primigravidae across all plausible parameter ranges, while ICERs in multigravidae were highly sensitive to programme costs and vaccine efficacy. Cost-effectiveness acceptability curves demonstrated that vaccination becomes favourable for primigravidae at relatively low willingness-to-pay thresholds. Conclusions: A placental malaria vaccine delivered before pregnancy has high potential to be cost-effective in endemic areas when targeted to protect primigravidae. These findings support prioritised deployment strategies and highlight the value of early economic modelling to inform vaccine development and policy planning.
Open AccessModelling the Cost-Effectiveness of a Placental Malaria Vaccine in Sub-Saharan Africa
Introduction: Placental malaria increases the risk of adverse birth outcomes. Current preventive measures are undermined by poor coverage, growing resistance to chemo-preventive and therapeutic drugs, and vector eliminating insecticides. Candidate placental malaria (PM) vaccines (PAMVAC and PRIMVAC) have shown safety and immunogenicity in Phase I trials, but empirical evidence on their potential population-level value is lacking. This study modelled the expected cost-effectiveness of a PM vaccine administered before pregnancy. Methods: A decision-analytic model compared two strategies from the provider’s perspective: vaccinating women of childbearing age versus no vaccination. The model incorporated gravidity-specific risks of PM, neonatal mortality and the malaria attributable fractions from the literature. Since the efficacy of a PM vaccine for malaria prevention is unknown, we assumed a 40% efficacy and varied this estimate widely in sensitivity analyses. Primary outcomes were incremental cost-effectiveness ratios (ICERs) per perinatal disability adjusted life years (DALYs) averted. Baseline, best-case, and worst-case scenarios were analysed. One-way and probabilistic sensitivity analyses were used to assess parameter uncertainty. Cost-effectiveness was defined as an ICER below half of sub- Saharan Africa’s 2025 GDP per capita ($1556). Results: The vaccine was most cost-effective among primigravidae. Under baseline assumptions (40% efficacy; 30% uptake; $5 dose price), the ICER was $321 per perinatal DALY averted for primigravidae versus $4444 for multigravidae. Best-case assumptions further improved cost-effectiveness ($225 vs. $3148). Sensitivity analyses showed robust cost-effectiveness for primigravidae across all plausible parameter ranges, while ICERs in multigravidae were highly sensitive to programme costs and vaccine efficacy. Cost-effectiveness acceptability curves demonstrated that vaccination becomes favourable for primigravidae at relatively low willingness-to-pay thresholds. Conclusions: A placental malaria vaccine delivered before pregnancy has high potential to be cost-effective in endemic areas when targeted to protect primigravidae. These findings support prioritised deployment strategies and highlight the value of early economic modelling to inform vaccine development and policy planning.
- Open Access
Cost-Effectiveness of the IMPALA Monitoring System for Hospitalised Children in Low-Resource Settings: A Pragmatic Before-and-After Study
Background: Staff shortages, limited training, and inadequate hospital equipment often delay responses to patient deterioration in low-resource settings. The IMPALA continuous monitoring system was developed to support proactive care for critically ill children in such settings. This study evaluated IMPALA cost-effectiveness compared with current practice manual intermittent monitoring from provider and societal perspectives. Methods: We conducted an economic evaluation based on a before-and-after cohort of children (0-180 months) admitted to Zomba Central Hospital (ZCH) and St. Luke’s Hospital (SLH), Malawi (2022-2024), where IMPALA was implemented in high-dependency units (HDUs). Targeted maximum likelihood estimation assessed percentage point (pp) differences in mortality, critical illness events (CIEs), disability-adjusted life years (DALYs), and costs (medical, non-medical, indirect). Incremental cost-effectiveness ratios (ICERs) and cost-effectiveness probabilities were calculated for different willingness-to-pay thresholds. Results: At ZCH paediatric ward, 1,840 pre- and 6,255 post-IMPALA children were included; 248 and 736 were admitted to the HDU. Ward mortality decreased (3.7%–2.8%), with an adjusted 1.9pp reduction (95%CI: - 3.8;-0.6). At ZCH-HDU, mortality slightly increased (8.1%–9.0%), but IMPALA was associated with an adjusted 9.8pp reduction (95%CI: −26.5;5.0), a 47.1pp decrease in CIEs (95%CI: −52.9;-41.8), and 5.4 DALYs averted (95%CI: −14.2;3.1). At SLH paediatric ward, mortality decreased (4.0%–2.1%), with an adjusted 1.6pp reduction (95%CI: −3.2;-0.2), a 25.5pp decrease in CIEs (95% CI: −30.1;-20.9), and 1.0 DALYs averted (95% CI: −1.9;-0.1). Provider and societal costs decreased in both wards, but not in the HDU. IMPALA was dominant in wards and slightly more costly but more effective in the HDU (ICERs -$22.5–$0.4 per life saved). Cost-effectiveness probabilities ranged from 0.8–1.0 in wards and 0.3–1.0 in the HDU. Conclusion: IMPALA was highly cost-effective, reducing mortality by >40%, morbidity by >50%, increasing DALYs averted, shortening hospital stays, and lowering costs, with spillover benefits from HDUs to wards. Key messages: What is already known on this topic: Continuous monitoring reduces mortality in high-resource settings, but its (cost-)effectiveness in low-resource contexts is uncertain due to staff shortages, unstable power, and limited supplies. What this study adds: Tailored for low-resource settings, IMPALA monitoring system saves lives, reduces illness events, and lowers inpatient and societal costs. How this study might affect research, practice or policy: Findings support broader implementation of a tailored continuous monitoring system to improve paediatric outcomes in low-resource settings.
Open AccessCost-Effectiveness of the IMPALA Monitoring System for Hospitalised Children in Low-Resource Settings: A Pragmatic Before-and-After Study
Background: Staff shortages, limited training, and inadequate hospital equipment often delay responses to patient deterioration in low-resource settings. The IMPALA continuous monitoring system was developed to support proactive care for critically ill children in such settings. This study evaluated IMPALA cost-effectiveness compared with current practice manual intermittent monitoring from provider and societal perspectives. Methods: We conducted an economic evaluation based on a before-and-after cohort of children (0-180 months) admitted to Zomba Central Hospital (ZCH) and St. Luke’s Hospital (SLH), Malawi (2022-2024), where IMPALA was implemented in high-dependency units (HDUs). Targeted maximum likelihood estimation assessed percentage point (pp) differences in mortality, critical illness events (CIEs), disability-adjusted life years (DALYs), and costs (medical, non-medical, indirect). Incremental cost-effectiveness ratios (ICERs) and cost-effectiveness probabilities were calculated for different willingness-to-pay thresholds. Results: At ZCH paediatric ward, 1,840 pre- and 6,255 post-IMPALA children were included; 248 and 736 were admitted to the HDU. Ward mortality decreased (3.7%–2.8%), with an adjusted 1.9pp reduction (95%CI: - 3.8;-0.6). At ZCH-HDU, mortality slightly increased (8.1%–9.0%), but IMPALA was associated with an adjusted 9.8pp reduction (95%CI: −26.5;5.0), a 47.1pp decrease in CIEs (95%CI: −52.9;-41.8), and 5.4 DALYs averted (95%CI: −14.2;3.1). At SLH paediatric ward, mortality decreased (4.0%–2.1%), with an adjusted 1.6pp reduction (95%CI: −3.2;-0.2), a 25.5pp decrease in CIEs (95% CI: −30.1;-20.9), and 1.0 DALYs averted (95% CI: −1.9;-0.1). Provider and societal costs decreased in both wards, but not in the HDU. IMPALA was dominant in wards and slightly more costly but more effective in the HDU (ICERs -$22.5–$0.4 per life saved). Cost-effectiveness probabilities ranged from 0.8–1.0 in wards and 0.3–1.0 in the HDU. Conclusion: IMPALA was highly cost-effective, reducing mortality by >40%, morbidity by >50%, increasing DALYs averted, shortening hospital stays, and lowering costs, with spillover benefits from HDUs to wards. Key messages: What is already known on this topic: Continuous monitoring reduces mortality in high-resource settings, but its (cost-)effectiveness in low-resource contexts is uncertain due to staff shortages, unstable power, and limited supplies. What this study adds: Tailored for low-resource settings, IMPALA monitoring system saves lives, reduces illness events, and lowers inpatient and societal costs. How this study might affect research, practice or policy: Findings support broader implementation of a tailored continuous monitoring system to improve paediatric outcomes in low-resource settings.
- Open Access
- 30 May 2025
- Published by MDPI AG in Antibiotics
- Vol. 14 (6) , 562
Prevalence of Extended-Spectrum β-Lactamase-Producing Escherichia coli, Klebsiella pneumoniae and Enterobacter cloacae in Wastewater Effluent in Blantyre, Malawi
Background/Objectives: Wastewater treatment plants (WWTPs) serve as a sink for both antimicrobial residues and bacteria carrying resistant genes, which are later disseminated into the environment, facilitating the spread of antimicrobial resistance. This study investigated the presence of extended-spectrum beta-lactamase (ESBL) producing Escherichia coli (Ec), Klebsiella pneumoniae (Kp), and Enterobacter cloacae (Enc) in effluent from WWTP in Blantyre, Malawi, to generate evidence and provide baseline information for interventions. Methods: Selective chromogenic agar was used to identify ESBL-producing bacteria. Results: A total of 288 samples were collected between April 2023 and March 2024, and 97.6% (281/288) yielded one or more presumptive ESBL isolates. Bacterial growth was confirmed as 48.9% Ec (255/522), 33.0% Kp (172/522), and 10.0% Enc (52/522). Antibiotic susceptibility testing showed the highest resistance to ceftriaxone (Ec, 100.0%; Kp, 98.3%; Enc, 100.0%) and the lowest resistance to meropenem (Ec, 6.3%, Kp, 1.2%; Enc, 3.8%) among the antibiotics that were tested. Multiple antibiotic resistance phenotypes were observed in 73.1% of the isolates, with the most prevalent phenotype being amoxicillin + clavulanate/cotrimoxazole/doxycycline/ciprofloxacin/gentamicin/azithromycin/ceftriaxone (55, 15.7%). Conclusions: The study demonstrated ongoing environmental contamination with antibiotic-resistant bacteria from sewage effluent. Therefore, the functionality of WWTPs should be improved to minimize the release of these organisms into the environment.
- 30 May 2025
- Published by MDPI AG in Antibiotics
- Vol. 14 (6) , 562
Open AccessPrevalence of Extended-Spectrum β-Lactamase-Producing Escherichia coli, Klebsiella pneumoniae and Enterobacter cloacae in Wastewater Effluent in Blantyre, Malawi
Background/Objectives: Wastewater treatment plants (WWTPs) serve as a sink for both antimicrobial residues and bacteria carrying resistant genes, which are later disseminated into the environment, facilitating the spread of antimicrobial resistance. This study investigated the presence of extended-spectrum beta-lactamase (ESBL) producing Escherichia coli (Ec), Klebsiella pneumoniae (Kp), and Enterobacter cloacae (Enc) in effluent from WWTP in Blantyre, Malawi, to generate evidence and provide baseline information for interventions. Methods: Selective chromogenic agar was used to identify ESBL-producing bacteria. Results: A total of 288 samples were collected between April 2023 and March 2024, and 97.6% (281/288) yielded one or more presumptive ESBL isolates. Bacterial growth was confirmed as 48.9% Ec (255/522), 33.0% Kp (172/522), and 10.0% Enc (52/522). Antibiotic susceptibility testing showed the highest resistance to ceftriaxone (Ec, 100.0%; Kp, 98.3%; Enc, 100.0%) and the lowest resistance to meropenem (Ec, 6.3%, Kp, 1.2%; Enc, 3.8%) among the antibiotics that were tested. Multiple antibiotic resistance phenotypes were observed in 73.1% of the isolates, with the most prevalent phenotype being amoxicillin + clavulanate/cotrimoxazole/doxycycline/ciprofloxacin/gentamicin/azithromycin/ceftriaxone (55, 15.7%). Conclusions: The study demonstrated ongoing environmental contamination with antibiotic-resistant bacteria from sewage effluent. Therefore, the functionality of WWTPs should be improved to minimize the release of these organisms into the environment.
- Open Access
- 10 April 2025
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 5 (4) , e0004341
Cost-effectiveness analysis of alternative infant and neonatal rotavirus vaccination schedules in Malawi
Rotavirus is the leading cause of severe diarrhea among children under five worldwide, especially in low- and middle-income countries (LMICs). Although vaccination is the best strategy to prevent rotavirus, obstacles leading to poor vaccine effectiveness undermine its impact in LMICs. This study aimed to identify the optimal rotavirus vaccination strategy for Malawi by modeling vaccine impact and cost-effectiveness, comparing the current two-dose Rotarix vaccine schedule to two alternative vaccine delivery schedules and a next-generation neonatal vaccine (RV3-BB) from 2025-2034. The cost-effectiveness of rotavirus vaccine strategies in Malawi was evaluated from the government and societal perspectives using estimates of moderate-to-severe and non-severe rotavirus cases derived from a transmission dynamic model of rotavirus and published estimates of health-seeking behaviors and costs as inputs. A probabilistic sensitivity analysis was performed to evaluate the robustness of our results to parameter uncertainty. Over a ten-year time horizon, the current two-dose Rotarix strategy is predicted to avert over 1.5 million cases and 90,000 disability-adjusted life-years (DALYs) compared to no vaccination and is cost-effective at willingness-to-pay (WTP) thresholds above $105 per DALY averted from the government perspective. Adding a third dose at 14 weeks could avert an additional 1 million cases and 38,000 DALYs, while switching to the neonatal RV3-BB vaccine could avert 1.1 million cases and 41,000 DALYs compared to the current strategy. Whereas adding a third dose of Rotarix would cost $4.1-4.9 million, switching to the neonatal vaccine is expected to save $3.7 million compared to the current strategy. Considering the neonatal vaccine is not yet available, adding a third dose of Rotarix at 14 weeks of age is cost-effective at WTP thresholds above $138 per DALY averted. The neonatal vaccine offers a more cost-effective alternative to Malawi’s current rotavirus vaccine, while adding a third dose to the current strategy also provides substantial benefits.
- 10 April 2025
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 5 (4) , e0004341
Open AccessCost-effectiveness analysis of alternative infant and neonatal rotavirus vaccination schedules in Malawi
Rotavirus is the leading cause of severe diarrhea among children under five worldwide, especially in low- and middle-income countries (LMICs). Although vaccination is the best strategy to prevent rotavirus, obstacles leading to poor vaccine effectiveness undermine its impact in LMICs. This study aimed to identify the optimal rotavirus vaccination strategy for Malawi by modeling vaccine impact and cost-effectiveness, comparing the current two-dose Rotarix vaccine schedule to two alternative vaccine delivery schedules and a next-generation neonatal vaccine (RV3-BB) from 2025-2034. The cost-effectiveness of rotavirus vaccine strategies in Malawi was evaluated from the government and societal perspectives using estimates of moderate-to-severe and non-severe rotavirus cases derived from a transmission dynamic model of rotavirus and published estimates of health-seeking behaviors and costs as inputs. A probabilistic sensitivity analysis was performed to evaluate the robustness of our results to parameter uncertainty. Over a ten-year time horizon, the current two-dose Rotarix strategy is predicted to avert over 1.5 million cases and 90,000 disability-adjusted life-years (DALYs) compared to no vaccination and is cost-effective at willingness-to-pay (WTP) thresholds above $105 per DALY averted from the government perspective. Adding a third dose at 14 weeks could avert an additional 1 million cases and 38,000 DALYs, while switching to the neonatal RV3-BB vaccine could avert 1.1 million cases and 41,000 DALYs compared to the current strategy. Whereas adding a third dose of Rotarix would cost $4.1-4.9 million, switching to the neonatal vaccine is expected to save $3.7 million compared to the current strategy. Considering the neonatal vaccine is not yet available, adding a third dose of Rotarix at 14 weeks of age is cost-effective at WTP thresholds above $138 per DALY averted. The neonatal vaccine offers a more cost-effective alternative to Malawi’s current rotavirus vaccine, while adding a third dose to the current strategy also provides substantial benefits.
- Open Access
- 26 March 2025
- Published by MDPI AG in Preprints.org
Prevalence of Extended Spectrum β-Lactamase-Producing Escherichia coli, Klebsiella pneumoniae and Enterobacter cloacae in Wastewater Effluent in Blantyre, Malawi
Background/Objectives: Wastewater treatment plants (WWTP) serve as a sink for both antimicrobial residues and bacteria carrying resistant genes which are later disseminated into the environment, facilitating the spread of antimicrobial resistance. This study investigated the presence of extended spectrum beta-lactamase (ESBL) producing Escherichia coli (Ec), Klebsiella pneumoniae (Kp) and Enterobacter cloacae (Enc) in effluent from WWTP in Blantyre, Malawi, to generate evidence and provide baseline information for interventions. Methods: Selective chromogenic agar was used to identify ESBL-producing bacteria. Results: A total of 288 samples were collected between April, 2023 and March, 2024 and 97.6% (281/288) yielded one or more presumptive ESBL isolates. Bacterial growth was confirmed as 48.9% Ec (255/522), 33.0% Kp (172/522) and 10.0% Enc (52/522). Antibiotic susceptibility testing showed higher resistance to ceftriaxone (Ec, 100.0%; Kp, 98.3%; Enc, 100.0%) and lower resistance to meropenem (Ec, 6.3%, Kp, 1.2%; Enc, 3.8%) among the antibiotics that were tested. Multiple antibiotic resistance phenotypes were observed in 73.1% of the isolates with the most prevalent phenotype as AUG-SXT-DXT-CIP-GM-ATH-CRO (55, 15.7%). Conclusions: The study demonstrated ongoing environmental contamination with antibiotic resistant bacteria from sewage effluent. Therefore, the functionality of WWTP should be improved to minimize the release of these organisms into the environment.
- 26 March 2025
- Published by MDPI AG in Preprints.org
Open AccessPrevalence of Extended Spectrum β-Lactamase-Producing Escherichia coli, Klebsiella pneumoniae and Enterobacter cloacae in Wastewater Effluent in Blantyre, Malawi
Background/Objectives: Wastewater treatment plants (WWTP) serve as a sink for both antimicrobial residues and bacteria carrying resistant genes which are later disseminated into the environment, facilitating the spread of antimicrobial resistance. This study investigated the presence of extended spectrum beta-lactamase (ESBL) producing Escherichia coli (Ec), Klebsiella pneumoniae (Kp) and Enterobacter cloacae (Enc) in effluent from WWTP in Blantyre, Malawi, to generate evidence and provide baseline information for interventions. Methods: Selective chromogenic agar was used to identify ESBL-producing bacteria. Results: A total of 288 samples were collected between April, 2023 and March, 2024 and 97.6% (281/288) yielded one or more presumptive ESBL isolates. Bacterial growth was confirmed as 48.9% Ec (255/522), 33.0% Kp (172/522) and 10.0% Enc (52/522). Antibiotic susceptibility testing showed higher resistance to ceftriaxone (Ec, 100.0%; Kp, 98.3%; Enc, 100.0%) and lower resistance to meropenem (Ec, 6.3%, Kp, 1.2%; Enc, 3.8%) among the antibiotics that were tested. Multiple antibiotic resistance phenotypes were observed in 73.1% of the isolates with the most prevalent phenotype as AUG-SXT-DXT-CIP-GM-ATH-CRO (55, 15.7%). Conclusions: The study demonstrated ongoing environmental contamination with antibiotic resistant bacteria from sewage effluent. Therefore, the functionality of WWTP should be improved to minimize the release of these organisms into the environment.
- Open Access
Cost-effectiveness Analysis of Alternative Infant and Neonatal Rotavirus Vaccination Schedules in Malawi
Rotavirus is the leading cause of severe diarrhea among children under five worldwide, especially in low- and middle-income countries (LMICs). Although vaccination is the best strategy for preventing rotavirus infection, obstacles leading to poor vaccine effectiveness undermine its impact in LMICs. This study aimed to evaluate the impact and cost-effectiveness of the current two-dose Rotarix vaccine schedule in Malawi compared to two alternative vaccine delivery schedules and a next-generation neonatal vaccine (RV3-BB) from 2025-2034. The cost-effectiveness of rotavirus vaccine strategies in Malawi was evaluated from both the government and societal perspectives using estimates of moderate-to-severe and non-severe rotavirus cases derived from a mathematical model of rotavirus transmission dynamics and published estimates of health-seeking behaviors and costs as inputs. A probabilistic sensitivity analysis was performed to evaluate the robustness of our results to parameter uncertainty. Over a ten-year time horizon, the current two-dose strategy was predicted to avert over 1.5 million cases and 90,000 disability-adjusted life-years (DALYs) and cost $104.87 per DALY averted compared to no vaccination from the government perspective. Adding a third dose at 14 weeks could avert about 1 million more cases and cost $5 million more than the current strategy. The neonatal RV3-BB vaccine could avert 1.1 million cases and 41,000 DALYs due to rotavirus and save about $3.7 million compared to the current strategy. The current rotavirus vaccine program in Malawi is cost-effective and saves lives compared to no vaccination. However, adding a third dose is likely to be cost-effective at a willingness to pay (WTP) of $138.38 per DALY averted, while switching to the neonatal RV3-BB vaccine when available is likely to be cost-effective at a WTP above $45.89 per DALY averted.
Open AccessCost-effectiveness Analysis of Alternative Infant and Neonatal Rotavirus Vaccination Schedules in Malawi
Rotavirus is the leading cause of severe diarrhea among children under five worldwide, especially in low- and middle-income countries (LMICs). Although vaccination is the best strategy for preventing rotavirus infection, obstacles leading to poor vaccine effectiveness undermine its impact in LMICs. This study aimed to evaluate the impact and cost-effectiveness of the current two-dose Rotarix vaccine schedule in Malawi compared to two alternative vaccine delivery schedules and a next-generation neonatal vaccine (RV3-BB) from 2025-2034. The cost-effectiveness of rotavirus vaccine strategies in Malawi was evaluated from both the government and societal perspectives using estimates of moderate-to-severe and non-severe rotavirus cases derived from a mathematical model of rotavirus transmission dynamics and published estimates of health-seeking behaviors and costs as inputs. A probabilistic sensitivity analysis was performed to evaluate the robustness of our results to parameter uncertainty. Over a ten-year time horizon, the current two-dose strategy was predicted to avert over 1.5 million cases and 90,000 disability-adjusted life-years (DALYs) and cost $104.87 per DALY averted compared to no vaccination from the government perspective. Adding a third dose at 14 weeks could avert about 1 million more cases and cost $5 million more than the current strategy. The neonatal RV3-BB vaccine could avert 1.1 million cases and 41,000 DALYs due to rotavirus and save about $3.7 million compared to the current strategy. The current rotavirus vaccine program in Malawi is cost-effective and saves lives compared to no vaccination. However, adding a third dose is likely to be cost-effective at a willingness to pay (WTP) of $138.38 per DALY averted, while switching to the neonatal RV3-BB vaccine when available is likely to be cost-effective at a WTP above $45.89 per DALY averted.